- About
- Research
- Director
- Center’s Leadership & Administration
- Associate Research Scientists
- Postdoctoral Fellows
- Doctoral Students
- Visiting Members
- Publications
- Important Links
- Contact Us
Khan MM, Yalamarty SSK, Rajmalani BA, Filipczak N, Torchilin VP.
Recent strategies to overcome breast cancer resistance.
Crit Rev Oncol Hematol. 2024;197: 104351.
Yalamarty SSK, Filipczak N, Pathrikar T, Cotter C, Ataide JA, Luther E, et al.
Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.
Drug Deliv Transl Res. 2024.
Ataide JA, Coco JC, Dos Santos EM, Beraldo-Araujo V, Silva JRA, de Castro KC, et al.
Co-Encapsulation of Drugs for Topical Application-A Review.
Molecules. 2023;28(3)
Davatgaran Taghipour Y, Salehi R, Zarebkohan A, Zakeri Z, Khordadmehr M, Saeedi Honar Y, et al.
Dual targeting salinomycin-loaded smart nanomicelles for enhanced accumulation and therapeutic outcome in breast cancer.
Int J Pharm. 2023;642:123095.
Filipczak N, Li X, Saawant GR, Yalamarty SSK, Luther E, Torchilin VP.
Antibody-modified DNase I micelles specifically recognize the neutrophil extracellular traps (NETs) and promote their degradation.
J Control Release. 2023;354:109-19.
Moussa M, Chowdhury MR, Mwin D, Fatih M, Selveraj G, Abdelmonem A, et al.
Combined thermal ablation and liposomal granulocyte-macrophage colony stimulation factor increases immune cell trafficking in a small animal tumor model.
PLoS One. 2023;18(10):e0293141.
Subhan MA, Filipczak N, Torchilin VP.
Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers.
Pharmaceuticals (Basel). 2023;16(7).
Subhan MA, Parveen F, Filipczak N, Yalamarty SSK, Torchilin VP.
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis.
J Pers Med. 2023;13(3).
Subhan MA, Parveen F, Shah H, Yalamarty SSK, Ataide JA, Torchilin VP.
Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type.
Cancers (Basel) . 2023;15(8).
Subhan MA, Torchilin VP.
Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate.
Pharmaceutics . 2023;15(4).
Subhan MA, Torchilin VP.
Biopolymer-Based Nanosystems for siRNA Drug Delivery to Solid Tumors including Breast Cancer.
Pharmaceutics. 2023;15(1).
Yalamarty SSK, Filipczak N, Khan MM, Torchilin VP.
Role of circular RNA and its delivery strategies to cancer - An overview.
J Control Release. . 2023;356:306-15.
Yalamarty SSK, Filipczak N, Li X, Subhan MA, Parveen F, Ataide JA, et al.
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).
Cancers (Basel) .2023;15(7).
Yalamarty SSK, Filipczak N, Pathrikar T, Cotter C, Ataide JA, Luther E, et al.
Evaluation of mAb 2C5-modified dendrimer-based micelles for the co-delivery of siRNA and chemotherapeutic drug in xenograft mice model.
Res Sq. 2023.
Khan MM, Torchilin VP.
Recent Trends in Nanomedicine-Based Strategies to Overcome Multidrug Resistance in Tumors.
Cancers (Basel) . 2022;14(17).
Li X, Zhou X, Liu J, Zhang J, Feng Y, Wang F, et al.
Liposomal Co-delivery of PD-L1 siRNA/Anemoside B4 for Enhanced Combinational Immunotherapeutic Effect.
ACS Appl Mater Interfaces. . 2022;14(25):28439-54.
Parveen F, Madni A, Torchilin VP, Rehman M, Jamshaid T, Filipczak N, et al.
Investigation of Eutectic Mixtures of Fatty Acids as a Novel Construct for Temperature-Responsive Drug Delivery.
Int J Nanomedicine. 2022;17:2413-34.
Taghipour YD, Zarebkohan A, Salehi R, Rahimi F, Torchilin VP, Hamblin MR, et al.
An update on dual targeting strategy for cancer treatment.
J Control Release . 2022;349:67-96.
Yalamarty SSK, Filipczak N, Li X, Pathrikar TV, Cotter C, Torchilin VP.
Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers.
Pharmaceutics . 2022;14(7).
Subhan MA, Torchilin VP.
Neutrophils as an emerging therapeutic target and tool for cancer therapy.
Life Sci. 2021 Sep 11;285:119952.
Attia SA, Li X, Filipczak N, Costa DF, Torchilin VP.Modification of Nanoparticles with Transferrin for Targeting Brain Tissues.
Methods Mol Biol. 2021;2355:49-56.
Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP.
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment.
J Pers Med.2021 Jun 18;11(6):571.
Pappalardo JS, Salmaso S, Levchenko TS, Mastrotto F, Bersani S, Langellotti CA, Vermeulen M, Ghersa F, Quattrocchi V, Zamorano PI, Hartner WC, Toniutti M, Musacchio T, Torchilin VP.<
Characterization of a Nanovaccine Platform Based on an α1,2-Mannobiose Derivative Shows Species-non-specific Targeting to Human, Bovine, Mouse, and Teleost Fish Dendritic Cells.
Mol Pharm. 2021 Jul 5;18(7):2540-2555.
Raval N, Maheshwari R, Shukla H, Kalia K, Torchilin VP, Tekade RK.
Multifunctional polymeric micellar nanomedicine in the diagnosis and treatment of cancer.
Mater Sci Eng C Mater Biol Appl. 2021 Jul;126:112186.
Filipczak N, Yalamarty SSK, Li X, Parveen F, Torchilin V.
Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases.
Molecules. 2021 May 31;26(11):3304.
Subhan MA, Attia SA, Torchilin VP.
Advances in siRNA delivery strategies for the treatment of MDR cancer.
Life Sci. 2021 Jun 1;274:119337.
Narayanaswamy R, Torchilin VP.
Targeted Delivery of Combination Therapeutics Using Monoclonal Antibody 2C5-Modified Immunoliposomes for Cancer Therapy.
Pharm Res. 2021 Mar;38(3):429-450.
Khan MM, Filipczak N, Torchilin VP.
Cell penetrating peptides: A versatile vector for co-delivery of drug and genes in cancer.
J Control Release. 2021 Feb 10;330:1220-1228.
Kornuta CA, Bidart JE, Soria I, Gammella M, Quattrocchi V, Pappalardo JS, Salmaso S, Torchilin VP, Cheuquepán Valenzuela F, Hecker YP, Moore DP, Zamorano PI, Langellotti CA.
MANα1-2MAN decorated liposomes enhance the immunogenicity induced by a DNA vaccine against BoHV-1.
Transbound Emerg Dis. 2021 Mar;68(2):587-597.
Mendes LP, Rostamizadeh K, Gollomp K, Myerson JW, Marcos-Contreras OA, Zamora M, Luther E, Brenner JS, Filipczak N, Li X, Torchilin VP.
Monoclonal antibody 2C5 specifically targets neutrophil extracellular traps.
MAbs. 2020 Jan-Dec;12(1):1850394.
Shahriari M, Torchilin VP, Taghdisi SM, Abnous K, Ramezani M, Alibolandi M.
“Smart” self-assembled structures: toward intelligent dual responsive drug delivery systems.
Biomater Sci. 2020 Oct 27;8(21):5787-5803.
Joshi U, Filipczak N, Khan MM, Attia SA, Torchilin V.
Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells.
Int J Pharm. 2020 Nov 30;590:119915
Campos PM, Praça FG, Mussi SV, Figueiredo SA, Fantini MCA, Fonseca MJV, Torchilin VP, Bentley MVLB.
Liquid crystalline nanodispersion functionalized with cell-penetrating peptides improves skin penetration and anti-inflammatory effect of lipoic acid after in vivo skin exposure to UVB radiation.
Drug Deliv Transl Res. 2020 Dec;10(6):1810-1828.
Zhang X, Pan J, Yao M, Palmerston Mendes L, Sarisozen C, Mao S, Torchilin VP.
Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery.
Eur J Pharm Biopharm. 2020 Sep;154:43-49.
Filipczak N, Pan J, Yalamarty SSK, Torchilin VP.
Recent advancements in liposome technology.
Adv Drug Deliv Rev. 2020;156:4-22.
Subhan MA, Torchilin VP.
siRNA based drug design, quality, delivery, and clinical translation.
Nanomedicine. 2020 Oct;29:102239.
Khan MM, Madni A, Filipczak N, Pan J, Rehman M, Rai N, Attia SA, Torchilin VP.
Folate targeted lipid chitosan hybrid nanoparticles for enhanced anti-tumor efficacy.
Nanomedicine. 2020 Aug;28:102228.
Pan J, Attia SA, Subhan MA, Filipczak N, Mendes LP, Li X, Kishan Yalamarty SS, Torchilin VP.
Monoclonal Antibody 2C5-Modified Mixed Dendrimer Micelles for Tumor-Targeted Codelivery of Chemotherapeutics and siRNA.
Mol Pharm. 2020 May 4;17(5):1638-1647.
Mensah SA, Nersesyan AA, Harding IC, Lee CI, Tan X, Banerjee S, Niedre M, Torchilin VP, Ebong EE.
Flow-regulated endothelial glycocalyx determines metastatic cancer cell activity.
FASEB J. 2020 May;34(5):6166-6184
Mutlu-Agardan NB, Sarisozen C, Torchilin VP.
Cytotoxicity of Novel Redox Sensitive PEG<sub>2000</sub>-S-S-PTX Micelles against Drug-Resistant Ovarian and Breast Cancer Cells.
Pharm Res. 2020 Mar 12;37(3):65.
Bhatt H, Kiran Rompicharla SV, Ghosh B, Torchilin V, Biswas S.
Transferrin/α-tocopherol modified poly(amidoamine) dendrimers for improved tumor targeting and anticancer activity of paclitaxel.
Nanomedicine (Lond). 2019 Dec;14(24):3159-3176.
Filipczak N, Jaromin A, Piwoni A, Mahmud M, Sarisozen C, Torchilin V, Gubernator J.
A Triple Co-Delivery Liposomal Carrier That Enhances Apoptosis via an Intrinsic Pathway in Melanoma Cells.
Cancers (Basel). 2019 Dec 9;11(12):1982.
Subhan MA, Torchilin VP.
Efficient nanocarriers of siRNA therapeutics for cancer treatment.
Transl Res. 2019 Dec;214:62-91.
Mensah SA, Harding IC, Zhang M, Jaeggli MP, Torchilin VP, Niedre MJ, Ebong EE.
Metastatic cancer cell attachment to endothelium is promoted by endothelial glycocalyx sialic acid degradation.
AIChE J. 2019 Aug;65(8):e16634.
Khan MM, Madni A, Torchilin V, Filipczak N, Pan J, Tahir N, Shah H.
Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin.
Drug Deliv. 2019 Dec;26(1):765-772.
Hussein WM, Cheong YS, Liu C, Liu G, Begum AA, Attallah MA, Moyle PM, Torchilin VP, Smith R, Toth I.
Peptide-based targeted polymeric nanoparticles for siRNA delivery.
Nanotechnology. 2019 Oct 11;30(41):415604.
Costa DF, Sarisozen C, Torchilin VP.
Synthesis of Doxorubicin and miRNA Stimuli-Sensitive Conjugates for Combination Therapy.
Methods Mol Biol. 2019;1974:99-109.
Mendes LP, Sarisozen C, Luther E, Pan J, Torchilin VP.
Surface-engineered polyethyleneimine-modified liposomes as novel carrier of siRNA and chemotherapeutics for combination treatment of drug-resistant cancers.
Drug Deliv. 2019 Dec;26(1):443-458.
Pan J, Rostamizadeh K, Filipczak N, Torchilin VP.
Polymeric Co-Delivery Systems in Cancer Treatment: An Overview on Component Drugs’ Dosage Ratio Effect.
Molecules. 2019 Mar 15;24(6):1035.
Narayanaswamy R, Torchilin VP.
Hydrogels and Their Applications in Targeted Drug Delivery.
Molecules.2019 Feb 8;24(3).
Sarisozen C, Tan Y, Liu J, Bilir C, Shen L, Filipzcak N, Porter TM, Torchilin VP.
MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation.
J Drug Target. 2019 Jan 18:1-10.
Pan J, Mendes LP, Yao M, Filipczak N, Garai S, Thakur GA, Sarisozen C, Torchilin VP.
Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.
Eur J Pharm Biopharm. 2019 Mar;136:18-28.
Jhaveri A, Luther E, Torchilin V.
The effect of transferrin-targeted, resveratrol-loaded liposomes on neurosphere cultures of glioblastoma: Implications for targeting tumor-initiating cells.
J Drug Target. 2018 Nov 26:1-43.
El-Sawy HS, Al-Abd AM, Ahmed TA, El-Say KM, Torchilin VP.
Stimuli-Responsive Nano-Architecture Drug-Delivery Systems to Solid Tumor Micromilieu: Past, Present, and Future Perspectives.
ACS Nano. 2018 Nov 27;12(11):10636-10664.
Costa DF, Mendes LP, Torchilin VP.
The effect of low- and high-penetration light on localized cancer therapy.
Adv Drug Deliv Rev. 2018 Sep 12. pii: S0169-409X(18)30224-2.
Costa DF, Torchilin VP.
Micelle-like nanoparticles as siRNA and miRNA carriers for cancer therapy.
Biomed Microdevices. 2018 Jul 12;20(3):59.
Mutlu Agardan NB, Sarisozen C, Torchilin VP.
Redox-triggered intracellular siRNA delivery.
Chem Commun (Camb). 2018 Jun 14;54(49):6368-6371.
Joanitti GA, Sawant RS, Torchilin VP, Freitas SM, Azevedo RB.
Optimizing liposomes for delivery of Bowman-Birk protease inhibitors – Platforms for multiple biomedical applications.
Colloids Surf B Biointerfaces. 2018 Jul 1;167:474-482.
Upponi JR, Jerajani K, Nagesha DK, Kulkarni P, Sridhar S, Ferris C, Torchilin VP.
Polymeric micelles: Theranostic co-delivery system for poorly water-soluble drugs and contrast agents.
Biomaterials. 2018 Jul;170:26-36.
Ahmed M, Kumar G, Gourevitch S, Levchenko T, Galun E, Torchilin V, Goldberg SN.
Radiofrequency ablation (RFA)-induced systemic tumor growth can be reduced by suppression of resultant heat shock proteins.
Int J Hyperthermia. 2018 Nov;34(7):934-942.
Jhaveri A, Deshpande P, Pattni B, Torchilin V.
Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma.
J Control Release. 2018 May 10;277:89-101.
Deshpande P, Jhaveri A, Pattni B, Biswas S, Torchilin V.
Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Drug Deliv. 2018 Nov;25(1):517-532.
Sherif MS, Rehab TA, Hamdia ZA, Torchilin VP.
Cytotoxicity of propolis nanopreparations in cancer cell monolayers: multimode of action including apoptotsis and nitric oxide production.
Gen Physiol Biophys. 2018 Jan;37(1):101-110.
Wang T, Narayanaswamy R, Ren H, Gillespie JW, Petrenko VA, Torchilin VP. Phage-derived protein-mediated targeted chemotherapy of pancreatic cancer.
J Drug Target. 2018 Jun – Jul;26(5-6):505-515.
Kumar G, Goldberg SN, Gourevitch S, Levchenko T, Torchilin V, Galun E, Ahmed M.
Targeting STAT3 to Suppress Systemic Pro-Oncogenic Effects from Hepatic Radiofrequency Ablation.
Radiology. 2018 Feb;286(2):524-536.
Pattni BS, Jhaveri A, Dutta I, Baleja JD, Degterev A, Torchilin V.
Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG.
Int J Pharm. 2017 Oct 30;532(1):149-156.
Palmerston Mendes L, Pan J, Torchilin VP.
Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy.
Molecules. 2017 Aug 23;22(9).
Muddineti OS, Kumari P, Ghosh B, Torchilin VP, Biswas S.
d-α-Tocopheryl Succinate/Phosphatidyl Ethanolamine Conjugated Amphiphilic Polymer-Based Nanomicellar System for the Efficient Delivery of Curcumin and To Overcome Multiple Drug Resistance in Cancer.
ACS Appl Mater Interfaces. 2017 May 24;9(20):16778-16792.
Kohay H, Sarisozen C, Sawant R, Jhaveri A, Torchilin VP, Mishael YG.
PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity. Acta Biomater. 2017 Jun;55:443-454.
Aryasomayajula B, Salzano G, Torchilin VP.
Multifunctional Liposomes.
Methods Mol Biol. 2017;1530:41-61.
Vladimirov YA, Sarisozen C, Vladimirov GK, Filipczak N, Polimova AM, Torchilin VP.
The Cytotoxic Action of Cytochrome C/Cardiolipin Nanocomplex (Cyt-CL) on Cancer Cells in Culture.
Pharm Res. 2017 Jun;34(6):1264-1275.
Luther E, Mendes LP, Pan J, Costa DF, Torchilin VP.
Applications of label-free, quantitative phase holographic imaging cytometry to the development of multi-specific nanoscale pharmaceutical formulations.
Cytometry A.2017 May;91(5):412-423.
Mitragotri S, Lammers T, Bae YH, Schwendeman S, De Smedt S, Leroux JC, Peer D, Kwon IC, Harashima H, Kikuchi A, Oh YK, Torchilin V, Hennink W, Hanes J, Park K.
Drug Delivery Research for the Future: Expanding the Nano Horizons and Beyond.
J Control Release. 2017 Jan 28;246:183-184.
Erdogan S, Torchilin VP.
Gadolinium-Loaded Polychelating Polymer-Containing Tumor-Targeted Liposomes.
Methods Mol Biol. 2017;1522:179-192.
Yilmaz C, Sarisozen C, Torchilin V, Busnaina A.
Novel Nanoprinting for Oral Delivery of Poorly Soluble Drugs.
Methodist Debakey Cardiovasc J. 2016 Sep;12(3):157-162.
Zou W, Sarisozen C, Torchilin VP.
The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles.
J Drug Target. 2016 Oct 3:1-10.
M, Goldberg SN, Kumar G, Levchenko T, Torchilin V, Ahmed M.
Effect of thermal dose on heat shock protein expression after radio-frequency ablation with and without adjuvant nanoparticle chemotherapies.
Int J Hyperthermia. 2016 Dec;32(8):829-841.
Sarisozen C, Dhokai S, Tsikudo EG, Luther E, Rachman IM, Torchilin VP.
Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.
Eur J Pharm Biopharm. 2016 Aug 25. pii: S0939-6411(16)30464-7.
Oliveira MS, Aryasomayajula B, Pattni B, Mussi SV, Ferreira LA, Torchilin VP.
Solid lipid nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant cancer cells in monolayer and 3-D spheroid cancer cell models.
Int J Pharm. 2016 Oct 15;512(1):292-300.
Sánchez-Purrà M, Ramos V, Petrenko VA, Torchilin VP, Borrós S.
Double-targeted polymersomes and liposomes for multiple barrier crossing.
Int J Pharm. 2016 Sep 25;511(2):946-56.
Sriraman SK, Salzano G, Sarisozen C, Torchilin V.
Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid.
Eur J Pharm Biopharm. 2016 Aug;105:40-9.
Wang T, Narayanaswamy R, Ren H, Torchilin VP.
Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment.
Cancer Biol Ther. 2016 Jun 2;17(6):698-707.
Pattni BS, Nagelli SG, Aryasomayajula B, Deshpande PP, Kulkarni A, Hartner WC, Thakur G, Degterev A, Torchilin VP.
Targeting of Micelles and Liposomes Loaded with the Pro-Apoptotic Drug, NCL-240, into NCI/ADR-RES Cells in a 3D Spheroid Model.
Pharm Res. 2016 Oct;33(10):2540-51.
Salzano G, Costa DF, Sarisozen C, Luther E, Mattheolabakis G, Dhargalkar PP, Torchilin VP.
Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.
Small. 2016 Sep;12(35):4837-4848.
Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel E.
Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
Mol Cancer Ther. 2016 Oct;15(10):2282-2293.
Sarisozen C, Salzano G, Torchilin VP.
Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey.
Curr Pharm Biotechnol. 2016; 17(8):728-40.
Riehle R, Pattni B, Jhaveri A, Kulkarni A, Thakur G, Degterev A, Torchilin V.
Combination Nanopreparations of a Novel Proapoptotic Drug – NCL-240, TRAIL and siRNA.
Pharm Res. 2016 Jul;33(7):1587-601.
Klauber TC, Søndergaard RV, Sawant RR, Torchilin VP, Andresen TL.
Elucidating the role of free polycations in gene knockdown by siRNA polyplexes.
Acta Biomater. 2016 Apr 15;35:248-59.
Perche F, Biswas S, Patel NR, Torchilin VP.
Hypoxia-Responsive Copolymer for siRNA Delivery.
Methods Mol Biol. 2016;1372:139-62.
Sriraman SK, Pan J, Sarisozen C, Luther E, Torchilin V.
Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Mol Pharm. 2016 Jan 8;13 (2):428–437.
Sabhachandani P, Motwani V, Cohen N, Sarkar S, Torchilin V, Konry T.
Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform.
Lab Chip. 2016 Jan 26;16(3):497-505.
Jhaveri A, Torchilin V.
Intracellular delivery of nanocarriers and targeting to subcellular organelles.
Expert Opin Drug Deliv. 2016 Jan;13(1):49-70.
Sarisozen C, Salzano G, Torchilin VP.
Recent advances in siRNA delivery.
Biomol Concepts. 2015 Dec;6(5-6):321-41.
Lukianova-Hleb EY, Kim YS, Aryasomayajula B, Boulikas T, Phan J, Hung MC, Torchilin VP, O’Neill BE,
Lapotko DO.
Safety and efficacy of quadrapeutics versus chemoradiation in head and neck carcinoma xenograft model.
Am J Cancer Res. 2015 Nov 15;5(12):3534-47.
Sriraman SK, Geraldo V, Luther E, Degterev A, Torchilin V.
Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.
J Control Release. 2015 Dec 28;220(Pt A):160-8.
Salzano G, Costa DF, Torchilin VP.
siRNA Delivery by Stimuli-Sensitive Nanocarriers.
Curr Pharm Des. 2015;21(31):4566-73.
Patel NR, Aryasomayajula B, Abouzeid AH, Torchilin VP.
Cancer cell spheroids for screening of chemotherapeutics and drug-delivery systems.
Ther Deliv. 2015;6(4):509-20.
Pattni BS, Chupin VV, Torchilin VP.
New Developments in Liposomal Drug Delivery.
Chem Rev. 2015 Oct 14;115(19):10938-66.
Kitatani K, Usui T, Sriraman SK, Toyoshima M, Ishibashi M, Shigeta S, Nagase S, Sakamoto M, Ogiso H, Okazaki T, Hannun YA, Torchilin VP, Yaegashi N.
Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.
Oncogene. 2015 Sep 14.
Ahmed M, Kumar G, Navarro G, Wang Y, Gourevitch S, Moussa MH, Rozenblum N, Levchenko T, Galun E, Torchilin VP, Goldberg SN.
Systemic siRNA Nanoparticle-Based Drugs Combined with Radiofrequency Ablation for Cancer
Therapy.
PLoS One. 2015 Jul 8;10(7):e0128910.
Al-Abd AM, Aljehani ZK, Gazzaz RW, Fakhri SH, Jabbad AH, Alahdal AM, Torchilin VP.
Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors.
J Control Release. 2015 Dec 10;219:269-77.
Mussi SV, Parekh G, Pattekari P, Levchenko T, Lvov Y, Ferreira LA, Torchilin VP.
Improved pharmacokinetics and enhanced tumor growth inhibition using a nanostructured lipid carrier loaded with doxorubicin and modified with a layer-by-layer polyelectrolyte coating.
Int J Pharm. 2015 Nov 10;495(1):186-93.
Narayanaswamy R, Wang T, Torchilin VP.
Improving Peptide Applications Using Nanotechnology.
Curr Top Med Chem. 2016;16(3):253-70.
Salzano G, Torchilin VP.
Intracellular Delivery of Nanoparticles with Cell Penetrating Peptides.
Methods Mol Biol. 2015;1324:357-68.
Movassaghian S, Merkel OM, Torchilin VP.
Applications of polymer micelles for imaging and drug delivery.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):691-707.
Salzano G, Navarro G, Trivedi MS, De Rosa G, Torchilin VP.
Multifunctional polymeric micelles co-loaded with anti-survivin siRNA and paclitaxel overcome drug resistance in an animal model of ovarian cancer.
Mol Cancer Ther. 2015 Apr;14(4):1075-84.
Navarro G, Pan J, Torchilin VP.
Micelle-like Nanoparticles as Carriers for DNA and siRNA.
Mol Pharm. 2015 Feb 2;12(2):301-13. Review.
Kommagalla Y, Cornea S, Riehle R, Torchilin V, Degterev A, Ramana CV.
Optimization of the anti-cancer activity of phosphatidylinositol-3 kinase pathway inhibitor PITENIN-1: switching a thiourea with 1,2,3-triazole.
Medchemcomm. . 2014 Sep;5(9):1359-1363.
Wang T, Yang S, Mei LA, Parmar CK, Gillespie JW, Praveen KP, Petrenko VA,Torchilin VP.
Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumors.
Mol Cancer Ther. 2014 Dec;13(12):2864-75.
Moussa M, Goldberg SN, Kumar G, Sawant RR, Levchenko T, Torchilin V, Ahmed M.
Radiofrequency ablation-induced upregulation of hypoxia-inducible factor-1α can be suppressed with adjuvant bortezomib or liposomal chemotherapy.
J Vasc Interv Radiol. 2014 Dec;25(12):1972-82.
Essex S, Navarro G, Sabhachandani P, Chordia A, Trivedi M, Movassaghian S, Torchilin VP.
Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.
Gene Ther. 2015 Mar; 22(3): 257–266.
Torchilin VP.
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery.
Nat Rev Drug Discov. 2014 Nov;13(11):813-27. Review.
Sarisozen C, Abouzeid AH, Torchilin VP.
The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.
Eur J Pharm Biopharm. 2014 Oct;88(2):539-50.
Vandamme TF, Anton N, Torchilin V.
Targeted imaging.
Adv Drug Deliv Rev. 2014 Sep 30;76:1.
haveri A, Deshpande P, Torchilin V.
Stimuli-sensitive nanopreparations for combination cancer therapy.
J Control Release. 2014 Sep 28;190:352-70. Review.
Kommagalla Y, Cornea S, Riehle R, Torchilin V, Degterev A, Ramana CV.
Optimization of the anti-cancer activity of phosphatidylinositol-3 kinase pathway inhibitor PITENIN-1: switching a thiourea with 1,2,3-triazole.
Medchemcomm. 2014 Sep;5(9):1359-1363.
Moussa M, Goldberg SN, Kumar G, Sawant RR, Levchenko T, Torchilin VP, Ahmed M.
Nanodrug-enhanced radiofrequency tumor ablation: effect of micellar or liposomal carrier on drug delivery and treatment efficacy.
PLoS One. 2014 Aug18;9(8):e102727.
Memanishvili T, Zavradashvili N, Kupatadze N, Tugushi D, Gverdtsiteli M, Torchilin VP, Wandrey C, Baldi L, Manoli SS, Katsarava R.
Arginine-based biodegradable ether-ester polymers with low cytotoxicity as potential gene carriers.
Biomacromolecules. 2014 Aug 11;15(8):2839-48.
Lukianova-Hleb EY, Ren X, Sawant RR, Wu X, Torchilin VP, Lapotko DO.
On-demand intracellular amplification of chemoradiation with cancer-specific plasmonic nanobubbles.
Nat Med. 2014 Jul;20(7):778-84.
Sriraman SK, Aryasomayajula B, Torchilin VP.
Barriers to drug delivery in solid tumors.
Tissue Barriers. 2014 Jul 22;2:e29528. eCollection. Review.
Abouzeid AH, Patel NR, Sarisozen C, Torchilin VP.
Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells.
Pharm Res. 2014 Aug;31(8):1938-45.
Mussi SV, Sawant R, Perche F, Oliveira MC, Azevedo RB, Ferreira LA, Torchilin VP.
Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7/Adr cells.
Pharm Res. 2014 Aug;31(8):1882-92.
D’Arrigo G, Navarro G, Di Meo C, Matricardi P, Torchilin V.
Gellan gum nanohydrogel containing anti-inflammatory and anti-cancer drugs: a multi-drug delivery system for a combination therapy in cancer treatment.
Eur J Pharm Biopharm. 2014 May;87(1):208-16.
Parekh G, Pattekari P, Joshi C, Shutava T, DeCoster M, Levchenko T, Torchilin V, Lvov Y.
Layer-by-layer nanoencapsulation of camptothecin with improved activity.
Int J Pharm. 2014 Apr 25;465(1-2):218-27.
Jhaveri AM, Torchilin VP.
Multifunctional polymeric micelles for delivery of drugs and siRNA.
Front Pharmacol. 2014 Apr 25;5:77. eCollection Review.
Abouzeid AH, Patel NR, Torchilin VP.
Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer.
Int J Pharm. 2014 Apr 10;464(1-2):178-84.
Zhu L, Perche F, Wang T, Torchilin VP.
Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs.
Biomaterials. 2014 Apr;35(13):4213-22.
Perche F, Biswas S, Wang T, Zhu L, Torchilin VP.
Hypoxia-targeted siRNA delivery.
Angew Chem Int Ed Engl. 2014 Mar 24;53(13):3362-6.
Salzano G, Riehle R, Navarro G, Perche F, De Rosa G, Torchilin VP.
Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.
Cancer Lett. 2014 Feb 28;343(2):224-31.
Biswas S, Torchilin VP.
Nanopreparations for organelle-specific delivery in cancer.
Adv Drug Deliv Rev. 2014 Feb;66:26-41. Review.
Pappalardo JS, Langellotti CA, Di Giacomo S, Olivera V, Quattrocchi V, Zamorano PI, Hartner WC, Levchenko TS, Torchilin VP.
In vitro transfection of bone marrow-derived dendritic cells with TATp-liposomes.
Int J Nanomedicine. 2014 Feb 13;9:963-73.
Wang T, Hartner WC, Gillespie JW, Praveen KP, Yang S, Mei LA, Petrenko VA, Torchilin VP.
Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.
Nanomedicine. 2014 Feb;10(2):421-30.
Navarro G, Essex S, Sawant RR, Biswas S, Nagesha D, Sridhar S, de ILarduya CT, Torchilin VP.
Phospholipid-modified polyethylenimine-based nanopreparations for siRNA-mediated gene silencing: implications for transfection and the role of lipid components.
Nanomedicine. 2014 Feb;10(2):411-9.
Biswas S, Torchilin VP.
Dendrimers for siRNA Delivery.
Pharmaceuticals (Basel). 2013 Feb 4;6(2):161-83.
Sawant RR, Jhaveri AM, Koshkaryev A, Zhu L, Qureshi F, Torchilin VP.
Targeted transferrin-modified polymeric micelles: enhanced efficacy in vitro and in vivo in ovarian carcinoma.
Mol Pharm. 2014 Feb 3;11(2):375-81.
Apte A, Koren E, Koshkaryev A, Torchilin VP.
Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
Cancer Biol Ther. 2014 Jan;15(1):69-80.
Abouzeid AH, Patel NR, Rachman IM, Senn S, Torchilin VP.
Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin.
J Drug Target. 2013 Dec;21(10):994-1000.
Patel NR, Pattni BS, Abouzeid AH, Torchilin VP.
Nanopreparations to overcome multidrug resistance in cancer.
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1748-62. Review.
Zhu L, Wang T, Perche F, Taigind A, Torchilin VP.
Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety.
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17047-52.
Deshpande PP, Biswas S, Torchilin VP.
Current trends in the use of liposomes for tumor targeting.
Nanomedicine (Lond). 2013 Sep;8(9):1509-28. Review.
Sawant RR, Jhaveri AM, Koshkaryev A, Qureshi F, Torchilin VP.
The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy.
J Drug Target. 2013 Aug;21(7):630-8.
Perche F, Torchilin VP.
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting.
J Drug Deliv. 2013; 2013.
Biswas S, Dodwadkar NS, Deshpande PP, Parab S, Torchilin VP.
Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity.
Eur J Pharm Biopharm. 2013 Aug;84(3):517-25.
Moussa M, Goldberg SN, Tasawwar B, Sawant RR, Levchenko T, Kumar G, Torchilin VP, Ahmed M.
Adjuvant liposomal doxorubicin markedly affects radiofrequency ablation-induced effects on periablational microvasculature.
J Vasc Interv Radiol. 2013 Jul;24(7):1021-33.
Biswas S, Deshpande PP, Perche F, Dodwadkar NS, Sane SD, Torchilin VP.
Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer.
Cancer Lett. 2013 Jul 10;335(1):191-200.
Mahmoud SS, Torchilin VP.
Hormetic/cytotoxic effects of Nigella sativa seed alcoholic and aqueous extracts on MCF-7 breast cancer cells alone or in combination with doxorubicin.
Cell Biochem Biophys. 2013 Jul;66(3):451-60.
Koshkaryev A, Piroyan A, Torchilin VP.
Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition.
Cancer Lett. 2013 Jul 1;334(2):293-3
Thekkedath R, Koshkaryev A, Torchilin VP.
Lysosome-targeted octadecyl-rhodamine B-liposomes enhance lysosomal accumulation of glucocerebrosidase in Gaucher’s cells in vitro.
Nanomedicine (Lond). 2013 Jul;8(7):1055-65.
Abouzeid AH, Torchilin VP.
The role of cell cycle in the efficiency and activity of cancer nanomedicines.
Expert Opin Drug Deliv. 2013 Jun;10(6):775-86. Review.
Nedosekin DA, Sarimollaoglu M, Galanzha EI, Sawant R, Torchilin VP, Verkhusha VV, Ma J, Frank MH, Biris AS, Zharov VP.
Synergy of photoacoustic and fluorescence flow cytometry of circulating cells with negative and positive contrasts.
J Biophotonics. 2013 May;6(5):425-34.
Silindir M, Erdoğan S, Özer AY, Doğan AL, Tuncel M, Uğur Ö, Torchilin VP.
Nanosized multifunctional liposomes for tumor diagnosis and molecular imaging by SPECT/CT.
J Liposome Res. 2013 Mar;23(1):20-7.
Riehle RD, Cornea S, Degterev A, Torchilin V.
Micellar formulations of pro-apoptotic DM-PIT-1 analogs and TRAIL in vitro and in vivo.
Drug Deliv. 2013 Feb;20(2):78-85.
Movassaghian S, Moghimi HR, Shirazi FH, Koshkaryev A, Trivedi MS, Torchilin VP.
Efficient down-regulation of PKC-α gene expression in A549 lung cancer cells mediated by antisense oligodeoxynucleotides in dendrosomes.
Int J Pharm. 2013 Jan 30;441(1-2):82-91.
Wu H, Zhu L, Torchilin VP.
pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery.
Biomaterials. 2013 Jan;34(4):1213-22.
Biswas S, Deshpande PP, Navarro G, Dodwadkar NS, Torchilin VP.
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery.
Biomaterials. 2013 Jan;34(4):1289-301.
Koshkaryev A, Sawant R, Deshpande M, Torchilin V.
Immunoconjugates and long circulating systems: origins, current state of the art and future directions.
Adv Drug Deliv Rev. 2013 Jan;65(1):24-35.
Musacchio T, Torchilin VP.
siRNA delivery: from basics to therapeutic applications.
Front Biosci (Landmark Ed). 2013 Jan 1;18:58-79. Review.
Zhu L, Torchilin VP.
Stimulus-responsive nanopreparations for tumor targeting.
Integr Biol (Camb). 2013 Jan;5(1):96-107.
Torchilin V.
Next step in drug delivery: getting to individual organelles.
Drug Deliv Transl Res. 2012 Dec 1;2(6):415-417.
Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP.
Long-circulating PEG-PE micelles co-loaded with paclitaxel and elacridar (GG918) overcome multidrug resistance.
Drug Deliv. 2012 Nov;19(8):363-70.
Malima A, Siavoshi S, Musacchio T, Upponi J, Yilmaz C, Somu S, Hartner W, Torchilin V, Busnaina A.
Highly sensitive microscale in vivo sensor enabled by electrophoretic assembly of nanoparticles for multiple biomarker detection.
Lab Chip. 2012 Nov 21;12(22):4748-54.
Perche F, Patel NR, Torchilin VP.
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.
J Control Release. 2012 Nov 28;164(1):95-102.
Sawant RR, Jhaveri AM, Torchilin VP.
Immunomicelles for advancing personalized therapy.
Adv Drug Deliv Rev. 2012 Oct;64(13):1436-46. . Review.
Perche F, Torchilin VP.
Cancer cell spheroids as a model to evaluate chemotherapy protocols.
Cancer Biol Ther. 2012 Oct;13(12):1205-13.
Miao B, Skidan I, Yang J, You Z, Fu X, Famulok M, Schaffhausen B, Torchilin V, Yuan J, Degterev A.
Inhibition of cell migration by PITENINs: the role of ARF6.
Oncogene. 2012 Sep 27;31(39):4317-32.
Koren E, Torchilin VP.
Cell-penetrating peptides: breaking through to the other side.
Trends Mol Med. 2012 Jul;18(7):385-93. Review.
Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R, Nel A, Panaro NJ, Grodzinski P.
Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.
Clin Cancer Res. 2012 Jun 15;18(12):3229-41.
Xing C, Levchenko T, Guo S, Stins M, Torchilin VP, Lo EH.
Delivering minocycline into brain endothelial cells with liposome-based technology.
J Cereb Blood Flow Metab. 2012 Jun;32(6):983-8.
Biswas S, Dodwadkar NS, Piroyan A, Torchilin VP.
Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria.
Biomaterials. 2012 Jun;33(18):4773-82.
Koren E, Apte A, Jani A, Torchilin VP.
Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity.
J Control Release. 2012 Jun 10;160(2):264-73.
Sawant RR, Torchilin VP.
Challenges in development of targeted liposomal therapeutics.
AAPS J. 2012 Jun;14(2):303-15.
Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant RR, Torchilin V, Goldberg SN.
Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: reduced tumor growth and increased animal endpoint survival in a small animal tumor model.
J Control Release. 2012 Jun 10;160(2):239-44.
Biswas S, Dodwadkar NS, Deshpande PP, Torchilin VP.
Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo.
J Control Release. 2012 May 10;159(3):393-402.
Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP.
PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells.
Drug Deliv. 2012 May;19(4):169-76.
Etzerodt A, Maniecki MB, Graversen JH, Møller HJ, Torchilin VP, Moestrup SK.
Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163.
J Control Release. 2012 May 30;160(1):72-80.
Sawant RR, Sriraman SK, Navarro G, Biswas S, Dalvi RA, Torchilin VP.
Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery.
Biomaterials. 2012 May;33(15):3942-51.
Levchenko TS, Hartner WC, Torchilin VP.
Liposomes for cardiovascular targeting.
Ther Deliv. 2012 Apr;3(4):501-14. Review.
Zhu L, Kate P, Torchilin VP.
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.
ACS Nano. 2012 Apr 24;6(4):3491-8.
Dao KL, Sawant RR, Hendricks JA, Ronga V, Torchilin VP, Hanson RN.
Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells.
Bioconjug Chem. 2012 Apr 18;23(4):785-95.
Chernenko T, Sawant RR, Miljkovic M, Quintero L, Diem M, Torchilin V.
Raman microscopy for noninvasive imaging of pharmaceutical nanocarriers: intracellular distribution of cationic liposomes of different composition.
Mol Pharm. 2012 Apr 2;9(4):930-6.
Buyens K, De Smedt SC, Braeckmans K, Demeester J, Peeters L, van Grunsven LA, de Mollerat du Jeu X, Sawant R, Torchilin V, Farkasova K, Ogris M, Sanders NN.
Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design.
J Control Release. 2012 Mar28;158(3):362-70. Review.
Navarro G, Sawant RR, Biswas S, Essex S, Tros de Ilarduya C, Torchilin VP.
P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells.
Nanomedicine (Lond). 2012 Jan;7(1):65-78.
Shutava TG, Pattekari PP, Arapov KA, Torchilin VP, Lvov YM.
Architectural layer-by-layer assembly of drug nanocapsules with PEGylated polyelectrolytes.
Soft Matter. 2012 Jan 1;8(36):9418-9427.
Levchenko TS, Hartner WC, Torchilin VP.
Liposomes in diagnosis and treatment of cardiovascular disorders.
Methodist Debakey Cardiovasc J. 2012 Jan;8(1):36-41. Review.
Koshkaryev A, Piroyan A, Torchilin VP.
Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes.
Cancer Biol Ther. 2012 Jan 1;13(1):50-60.
Movassaghian S, Moghimi HR, Shirazi FH, Torchilin VP.
Dendrosome-dendriplex inside liposomes: as a gene delivery system.
J Drug Target. 2011 Dec;19(10):925-32.
Meerovich I, Koshkaryev A, Torchilin VP.
Kinetic and thermodynamic approaches to the drug targeting phenomena.
Curr Drug Discov Technol. 2011 Dec 1;8(4):287-300. Review.
Meerovich I, Koshkaryev A, Thekkedath R, Torchilin VP.
Screening and optimization of ligand conjugates for lysosomal targeting.
Bioconjug Chem. 2011 Nov 16;22(11):2271-82.
Biswas S, Dodwadkar NS, Sawant RR, Torchilin VP.
Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization.
Bioconjug Chem. 2011 Oct 19;22(10):2005-13.
Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant RR, Collins M, Signoretti S, Torchilin V, Goldberg SN.
Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model.
Int J Hyperthermia. 2011;27(6):527-38.
Wang T, Kulkarni N, D’Souza GG, Petrenko VA, Torchilin VP.
On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence matters.
Mol Pharm. 2011 Oct 3;8(5):1720-8.
Sawant RR, Torchilin VP.
Design and synthesis of novel functional lipid-based bioconjugates for drug delivery and other applications.
Methods Mol Biol. 2011;751:357-78.
Koshkaryev A, Thekkedath R, Pagano C, Meerovich I, Torchilin VP.
Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B.
J Drug Target. 2011 Sep;19(8):606-14.
Patel NR, Rathi A, Mongayt D, Torchilin VP.
Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.
Int J Pharm. 2011 Sep 15;416(1):296-9.
Wang T, Kulkarni N, Bedi D, D’Souza GG, Papahadjopoulos-Sternberg B, Petrenko VA, Torchilin VP.
In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein.
J Drug Target. 2011 Sep;19(8):597-605.
Biswas S, Dodwadkar NS, Sawant RR, Koshkaryev A, Torchilin VP.
Surface modification of liposomes with rhodamine-123-conjugated polymer results in
enhanced mitochondrial targeting.
J Drug Target. 2011 Aug;19(7):552-61.
Koren E, Torchilin VP.
Drug carriers for vascular drug delivery.
IUBMB Life. 2011 Aug;63(8):586-95. Review.
Koren E, Apte A, Sawant RR, Grunwald J, Torchilin VP.
Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements.
Drug Deliv. 2011 Jul;18(5):377-84.
Bedi D, Musacchio T, Fagbohun OA, Gillespie JW, Deinnocentes P, Bird RC, Bookbinder L, Torchilin VP, Petrenko VA.
Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes.
Nanomedicine. 2011 Jun;7(3):315-23.
Siavoshi S, Yilmaz C, Somu S, Musacchio T, Upponi JR, Torchilin VP, Busnaina A.
Size-selective template-assisted electrophoretic assembly of nanoparticles for biosensing applications.
Langmuir. 2011 Jun 7;27(11):7301-6.
Skidan I, Grunwald J, Thekkedath R, Degterev A, Torchilin V.
A HPLC method for the quantitative determination of N-(2-hydroxy-5-nitrophenylcarbamothioyl)-3,5-dimethylbenzamide in biological samples.
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jun 1;879(19):1610-6.
Pattekari P, Zheng Z, Zhang X, Levchenko T, Torchilin V, Lvov Y.
Top-down and bottom-up approaches in production of aqueous nanocolloids of low solubility drug paclitaxel.
Phys Chem Chem Phys. 2011 May 21;13(19):9014-9.
Wang T, Upponi JR, Torchilin VP.
Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies.
Int J Pharm. 2012 May 1;427(1):3-20.
Sawant R, Torchilin V.
Intracellular delivery of nanoparticles with CPPs.
Methods Mol Biol. 2011;683:431-51
Torchilin V.
Tumor delivery of macromolecular drugs based on the EPR effect.
Adv Drug Deliv Rev. 2011 Mar 18;63(3):131-5. Review.
Serda RE, Blanco E, Mack A, Stafford SJ, Amra S, Li Q, van de Ven A, Tanaka T, Torchilin VP, Wiktorowicz JE, Ferrari M.
Proteomic analysis of serum opsonins impacting biodistribution and cellular association of porous silicon microparticles.
Mol Imaging. 2011 Feb;10(1):43-55.
Sawant RR, Vaze O, D’Souza GG, Rockwell K, Torchilin VP.
Palmitoyl ascorbate-loaded polymeric micelles: cancer cell targeting and cytotoxicity.
Pharm Res. 2011 Feb;28(2):301-8.
Sawant RR, Vaze OS, Wang T, D’Souza GG, Rockwell K, Gada K, Khaw BA, Torchilin VP.
Palmitoyl ascorbate liposomes and free ascorbic acid: comparison of anticancer therapeutic effects upon parenteral administration.
Pharm Res. 2012 Feb;29(2):375-83.
Navarro G, Sawant RR, Essex S, Tros de Ilarduya C, Torchilin VP.
Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery.
Drug Deliv Transl Res. 2011 Feb 1;1(1):25-33.
Lvov YM, Pattekari P, Zhang X, Torchilin V.
Converting poorly soluble materials into stable aqueous nanocolloids.
Langmuir. 2011 Feb 1;27(3):1212-7.
Musacchio T, Torchilin VP.
Recent developments in lipid-based pharmaceutical nanocarriers.
Front Biosci (Landmark Ed). 2011 Jan 1;16:1388-412. Review.
Tirabassi RS, Ace CI, Levchenko T, Torchilin VP, Selin LK, Nie S, Guberski DL, Yang K.
A mucosal vaccination approach for herpes simplex virus type 2.
Vaccine. 2011 Jan 29;29(5):1090-8.
Yang W, Ahmed M, Elian M, Hady el-SA, Levchenko TS, Sawant RR, Signoretti S,Collins M, Torchilin VP, Goldberg SN.
Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model?
Radiology. 2010 Dec;257(3):685-96.
Miao B, Skidan I, Yang J, Lugovskoy A, Reibarkh M, Long K, Brazell T, Durugkar KA, Maki J, Ramana CV, Schaffhausen B, Wagner G, Torchilin V, Yuan J, Degterev A.
Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains.
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20126-31.
Papagiannaros A, Upponi J, Hartner W, Mongayt D, Levchenko T, Torchilin V.
Quantum dot loaded immunomicelles for tumor imaging.
BMC Med Imaging. 2010 Oct 18;10:22.
Sawant RR, Torchilin VP.
Multifunctionality of lipid-core micelles for drug delivery and tumour targeting.
Mol Membr Biol. 2010 Oct;27(7):232-46.
Patel NR, Hatziantoniou S, Georgopoulos A, Demetzos C, Torchilin VP, Weissig V, D’Souza GG.
Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol.
J Liposome Res. 2010 Sep;20(3):244-9.
Torchilin VP.
Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents.
Ther Deliv. 2010 Aug;1(2):257-72. Review.
Wang T, Petrenko VA, Torchilin VP.
Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity.
Mol Pharm. 2010 Aug 2;7(4):1007-14.
Musacchio T, Vaze O, D’Souza G, Torchilin VP.
Effective stabilization and delivery of siRNA: reversible siRNA-phospholipid conjugate in nanosized mixed polymeric micelles.
Bioconjug Chem. 2010 Aug 18;21(8):1530-6.
Wang T, Yang S, Petrenko VA, Torchilin VP.
Cytoplasmic delivery of liposomes into MCF-7 breast cancer cells mediated by cell-specific phage fusion coat protein.
Mol Pharm. 2010 Aug 2;7(4):1149-58.
Jayanna PK, Bedi D, Gillespie JW, DeInnocentes P, Wang T, Torchilin VP, Bird RC, Petrenko VA.
Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency.
Nanomedicine. 2010 Aug;6(4):538-46.
Sawant RR, Vaze OS, Rockwell K, Torchilin VP.
Palmitoyl ascorbate-modified liposomes as nanoparticle platform for ascorbate-mediated cytotoxicity and paclitaxel co-delivery.
Eur J Pharm Biopharm. 2010 Aug;75(3):321-6.
Wang T, D’Souza GG, Bedi D, Fagbohun OA, Potturi LP, Papahadjopoulos-Sternberg B, Petrenko VA, Torchilin VP.
Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.
Nanomedicine (Lond). 2010 Jun;5(4):563-74.
Sawant R, Torchilin V.
Intracellular transduction using cell-penetrating peptides.
Mol Biosyst. 2010 Apr;6(4):628-40
Sawant RR, Torchilin VP.
Polymeric micelles: polyethylene glycol-phosphatidylethanolamine (PEG-PE)-based micelles as an example.
Methods Mol Biol. 2010;624:131-49.
Torchilin VP.
Passive and active drug targeting: drug delivery to tumors as an example.
Handb Exp Pharmacol. 2010;(197):3-53. Review.
Solazzo SA, Ahmed M, Schor-Bardach R, Yang W, Girnun GD, Rahmanuddin S, Levchenko T, Signoretti S, Spitz DR, Torchilin V, Goldberg SN.
Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways.
Radiology. 2010 Apr;255(1):62-74.
Levchenko TS, Hartner WC, Verma DD, Bernstein EA, Torchilin VP.
ATP-loaded liposomes for targeted treatment in models of myocardial ischemia.
Methods Mol Biol. 2010;605:361-75.
Erdogan S, Torchilin VP.
Gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes.
Methods Mol Biol. 2010;605:321-34 .
Kale AA, Torchilin VP.
Environment-responsive multifunctional liposomes.
Methods Mol Biol. 2010;605:213-42.
Elbayoumi TA, Torchilin VP.
Current trends in liposome research.
Methods Mol Biol. 2010;605:1-27.
Hartner WC, Verma DD, Levchenko TS, Bernstein EA, Torchilin VP.
ATP-loaded liposomes for treatment of myocardial ischemia.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Sep-Oct;1(5):530-9. Review.
Salmaso S, Pappalardo JS, Sawant RR, Musacchio T, Rockwell K, Caliceti P, Torchilin VP.
Targeting glioma cells in vitro with ascorbate-conjugated pharmaceutical nanocarriers.
Bioconjug Chem. 2009 Dec;20(12):2348-55.
Musacchio T, Toniutti M, Kautz R, Torchilin VP.
1H NMR detection of mobile lipids as a marker for apoptosis: the case of anticancer drug-loaded liposomes and polymeric micelles.
Mol Pharm. 2009 Nov-Dec;6(6):1876-82.
LaBeaume P, Wager K, Falcone D, Li J, Torchilin V, Castro C, Holewa C, Kallmerten AE, Jones GB.
Synthesis, functionalization and photo-Bergman chemistry of enediyne bioconjugates.
Bioorg Med Chem. 2009 Sep 1;17(17):6292-300.
Grunwald J, Rejtar T, Sawant R, Wang Z, Torchilin VP.
TAT peptide and its conjugates: proteolytic stability.
Bioconjug Chem. 2009 Aug 19;20(8):1531-7.
Papagiannaros A, Kale A, Levchenko TS, Mongayt D, Hartner WC, Torchilin VP.
Near infrared planar tumor imaging and quantification using nanosized Alexa 750-labeled phospholipid micelles.
Int J Nanomedicine. 2009;4:123-31.
Kale AA, Torchilin VP.
Environment-Responsive Polymers for Coating of Pharmaceutical Nanocarriers.
Polym Sci Ser A Chem Phys. 2009 Jun;51(6):730-737.
Sawant RR, Torchilin VP.
Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo.
Int J Pharm. 2009 Jun 5;374(1-2):114-8.
Papagiannaros A, Levchenko T, Hartner W, Mongayt D, Torchilin V.
Quantum dots encapsulated in phospholipid micelles for imaging and quantification of tumors in the near-infrared region.
Nanomedicine. 2009 Jun;5(2):216-24.
Ko YT, Falcao C, Torchilin VP.
Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.
Mol Pharm. 2009 May-Jun;6(3):971-7.
Musacchio T, Laquintana V, Latrofa A, Trapani G, Torchilin VP.
PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect.
Mol Pharm. 2009 Mar-Apr;6(2):468-79.
Torchilin V.
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers.
Eur J Pharm Biopharm. 2009 Mar;71(3):431-44. Review.
Jayanna PK, Torchilin VP, Petrenko VA.
Liposomes targeted by fusion phage proteins.
Nanomedicine. 2009 Mar;5(1):83-9.
ElBayoumi TA, Torchilin VP.
Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
Clin Cancer Res. 2009 Mar 15;15(6):1973-80.
Pappalardo JS, Quattrocchi V, Langellotti C, Di Giacomo S, Gnazzo V, Olivera V, Calamante G, Zamorano PI, Levchenko TS, Torchilin VP.
Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes.
J Control Release. 2009 Feb 20;134(1):41-6.
Elbayoumi TA, Torchilin VP.
Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice.
Mol Pharm. 2009 Jan-Feb;6(1):246-54.
Ko YT, Hartner WC, Kale A, Torchilin VP.
Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide.
Gene Ther. 2009 Jan;16(1):52-9.
Ko YT, Kale A, Hartner WC, Papahadjopoulos-Sternberg B, Torchilin VP.
Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery.
J Control Release. 2009 Jan 19;133(2):132-8.
Veerabadran NG, Mongayt D, Torchilin V, Price RR, Lvov YM.
Organized shells on clay nanotubes for controlled release of macromolecules.
Macromol Rapid Commun. 2009 Jan 16;30(2):99-103.
Skidan I, Miao B, Thekkedath RV, Dholakia P, Degterev A, Torchilin V.
In vitro cytotoxicity of novel pro-apoptotic agent DM-PIT-1 in PEG-PE-based micelles alone and in combination with TRAIL.
Drug Deliv. 2009 Jan;16(1):45-51.
D’Souza GG, Wang T, Rockwell K, Torchilin VP.
Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action of encapsulated paclitaxel in vitro.
Pharm Res. 2008 Nov;25(11):2567-72.
Elbayoumi TA, Torchilin VP.
Liposomes for targeted delivery of antithrombotic drugs.
Expert Opin Drug Deliv. 2008 Nov;5(11):1185-98. Review.
Torchilin V.
Intracellular delivery of protein and peptide therapeutics.
Drug Discov Today Technol. 2008 Autumn;5(2-3):e95-e103.
Sawant RR, Sawant RM, Torchilin VP.
Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity.
Eur J Pharm Biopharm. 2008 Sep;70(1):51-7.
Torchilin V.
Antibody-modified liposomes for cancer chemotherapy.
Expert Opin Drug Deliv. 2008 Sep;5(9):1003-25. Review.
Sawant RM, Cohen MB, Torchilin VP, Rokhlin OW.
Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro.
J Drug Target. 2008 Aug;16(7):601-4.
Sawant RR, Sawant RM, Kale AA, Torchilin VP.
The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells.
J Drug Target. 2008 Aug;16(7):596-600.
Boddapati SV, D’Souza GG, Erdogan S, Torchilin VP, Weissig V.
Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo.
Nano Lett. 2008 Aug;8(8):2559-63.
Skidan I, Dholakia P, Torchilin V.
Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles.
J Drug Target. 2008 Jul;16(6):486-93.
Agarwal A, Lvov Y, Sawant R, Torchilin V.
Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology.
J Control Release. 2008 Jun 24;128(3):255-60.
Elbayoumi TA, Torchilin VP.
Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice.
Int J Pharm. 2008 Jun 5;357(1-2):272-9.
Yang K, Whalen BJ, Tirabassi RS, Selin LK, Levchenko TS, Torchilin VP, Kislauskis EH, Guberski DL.
A DNA vaccine prime followed by a liposome-encapsulated protein boost confers enhanced mucosal immune responses and protection.
J Immunol. 2008 May 1;180(9):6159-67.
Torchilin VP.
Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery.
Biopolymers. 2008;90(5):604-10.
Ljubimova JY, Fujita M, Ljubimov AV, Torchilin VP, Black KL, Holler E.
Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.
Nanomedicine (Lond). 2008 Apr;3(2):247-65.
Erdogan S, Medarova ZO, Roby A, Moore A, Torchilin VP.
Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes.
J Magn Reson Imaging. 2008 Mar;27(3):574-80.
Matthäus C, Kale A, Chernenko T, Torchilin V, Diem M.
New ways of imaging uptake and intracellular fate of liposomal drug carrier systems inside individual cells, based on Raman microscopy.
Mol Pharm. 2008 Mar-Apr;5(2):287-93.
Torchilin VP.
Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers.
Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):548-58.
Kale AA, Torchilin VP.
“Smart” drug carriers: PEGylated TATp-modified pH-sensitive liposomes.
J Liposome Res. 2007;17(3-4):197-203.
Torchilin VP.
Nanocarriers.
Pharm Res. 2007 Dec;24(12):2333-4.
Gupta B, Levchenko TS, Torchilin VP.
TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice.
Oncol Res. 2007;16(8):351-9.
Elbayoumi TA, Torchilin VP.
Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
Eur J Pharm Sci. 2007 Nov;32(3):159-68.
Verma DD, Hartner WC, Thakkar V, Levchenko TS, Torchilin VP.
Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction.
Pharm Res. 2007 Nov;24(11):2131-7.
Kale AA, Torchilin VP.
Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes.
J Drug Target. 2007 Aug-Sep;15(7-8):538-45.
Torchilin VP.
Tatp-mediated intracellular delivery of pharmaceutical nanocarriers.
Biochem Soc Trans. 2007 Aug;35(Pt 4):816-20. Review.
Gupta B, Torchilin VP.
Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
Cancer Immunol Immunother. 2007 Aug;56(8):1215-23.
Roby A, Erdogan S, Torchilin VP.
Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles.
Cancer Biol Ther. 2007 Jul;6(7):1136-42.
Torchilin VP.
Targeted pharmaceutical nanocarriers for cancer therapy and imaging.
AAPS J. 2007 May 11;9(2):E128-47. Review.
Elbayoumi TA, Pabba S, Roby A, Torchilin VP.
Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.
J Liposome Res. 2007;17(1):1-14.
Kale AA, Torchilin VP.
Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates.
Bioconjug Chem. 2007 Mar-Apr;18(2):363-70.
Torchilin VP.
Micellar nanocarriers: pharmaceutical perspectives.
Pharm Res. 2007 Jan;24(1):1-16. Epub 2006 Nov 16. Review.
Torchilin VP.
Multifunctional nanocarriers.
Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55.
Torchilin VP.
Application of nanomedical approaches in experimental and clinical oncology.
Anticancer Agents Med Chem. 2006 Nov;6(6):501.
Elbayoumi TA, Torchilin VP.
Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.
Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1196-205.
Erdogan S, Roby A, Torchilin VP.
Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes.
Mol Pharm. 2006 Sep-Oct;3(5):525-30.
Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP.
“SMART” drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers.
Bioconjug Chem. 2006 Jul-Aug;17(4):943-9.
Verma DD, Levchenko TS, Bernstein EA, Mongayt D, Torchilin VP.
ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model.
J Drug Target. 2006 Jun;14(5):273-80.
Torchilin VP.
Recent approaches to intracellular delivery of drugs and DNA and organelle targeting.
Annu Rev Biomed Eng. 2006;8:343-75. Review.
Dabholkar RD, Sawant RM, Mongayt DA, Devarajan PV, Torchilin VP.
Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux.
Int J Pharm. 2006 Jun 6;315(1-2):148-57.
Erdogan S, Roby A, Sawant R, Hurley J, Torchilin VP.
Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes.
J Liposome Res. 2006;16(1):45-55.
Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP.
siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene.
J Control Release. 2006 May 15;112(2):229-39.
Roby A, Erdogan S, Torchilin VP.
Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro.
Eur J Pharm Biopharm. 2006 Apr;62(3):235-40.
Gupta B, Torchilin VP.
Transactivating transcriptional activator-mediated drug delivery.
Expert Opin Drug Deliv. 2006 Mar;3(2):177-90. Review.
Torchilin VP.
Lipid-core micelles for targeted drug delivery.
Curr Drug Deliv. 2005 Oct;2(4):319-27. Review.
Gupta B, Levchenko TS, Mongayt DA, Torchilin VP.
Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo.
J Drug Target. 2005 Jul;13(6):337-43.
Verma DD, Hartner WC, Levchenko TS, Bernstein EA, Torchilin VP.
ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction.
Pharm Res. 2005 Dec;22(12):2115-20.
Mu L, Elbayoumi TA, Torchilin VP.
Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin.
Int J Pharm. 2005 Dec 8;306(1-2):142-9.
Verma DD, Levchenko TS, Bernstein EA, Torchilin VP.
ATP-loaded liposomes effectively protect mechanical functions of the myocardium from global ischemia in an isolated rat heart model.
J Control Release. 2005 Nov 28;108(2-3):460-71.
Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN.
Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time.
J Vasc Interv Radiol. 2005 Oct;16(10):1365-71. PubMed PMID: 16221908.
Boddapati SV, Tongcharoensirikul P, Hanson RN, D’Souza GG, Torchilin VP, Weissig V.
Mitochondriotropic liposomes.
J Liposome Res. 2005;15(1-2):49-58.
Leevy WM, Gammon ST, Levchenko T, Daranciang DD, Murillo O, Torchilin V, Piwnica-Worms D, Huettner JE, Gokel GW.
Structure-activity relationships, kinetics, selectivity, and mechanistic studies of synthetic hydraphile channels in bacterial and mammalian cells.
Org Biomol Chem. 2005 Oct 7;3(19):3544-50.
Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK.
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo.
Nat Med. 2005 Jun;11(6):678-82.
Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, Torchilin VP, Goldberg SN.
Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals.
Radiology. 2005 May;235(2):469-77.
Wang J, Mongayt D, Torchilin VP.
Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids.
J Drug Target. 2005 Jan;13(1):73-80.
Gupta B, Levchenko TS, Torchilin VP.
Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides.
Adv Drug Deliv Rev. 2005 Feb 28;57(4):637-51.
Torchilin VP.
Recent advances with liposomes as pharmaceutical carriers.
Nat Rev Drug Discov. 2005 Feb;4(2):145-60. Review.
Torchilin VP.
Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate.
Adv Drug Deliv Rev. 2005 Jan 2;57(1):95-109. Review.
Original website on archive.org:
https://web.archive.org/web/20240429165447/https://web.northeastern.edu/cpbn/publications/